# Harmony Biosciences Reports Preliminary Q2 Revenue of $261M and CFO Departure

> news · REPORTED · 2025-07-16

Harmony Biosciences announced preliminary Q2 2026 net product revenue of approximately $261 million for WAKIX and simultaneously disclosed that CFO Glenn Reicin stepped down effective July 16, 2026, causing shares to fall over 5%. The company reaffirmed full-year 2026 net revenue guidance of $1.0 to $1.04 billion.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases, with its lead product WAKIX (pitolisant) approved for narcolepsy.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-announces-preliminary-q2-revenue-cfo-transition-says-executive-s-departure-not-due-to-any-disagreement/cZZEXxNR7s0

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.